2007 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
John C. Byrd spends much of his time researching Chronic lymphocytic leukemia, Internal medicine, Immunology, Leukemia and Cancer research. Ibrutinib is the focus of his Chronic lymphocytic leukemia research. His studies deal with areas such as Venetoclax, breakpoint cluster region, Neutropenia and Bruton's tyrosine kinase as well as Ibrutinib.
His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine. His Leukemia research is multidisciplinary, incorporating perspectives in Cancer, Chemotherapy, Monoclonal, Myeloid and Myeloid leukemia. The Cancer research study combines topics in areas such as DNA methylation, Apoptosis, Molecular biology, Signal transduction and Kinase.
John C. Byrd focuses on Chronic lymphocytic leukemia, Internal medicine, Cancer research, Immunology and Oncology. His Chronic lymphocytic leukemia study is focused on Leukemia in general. In his work, Decitabine is strongly intertwined with Myeloid leukemia, which is a subfield of Leukemia.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. His Cancer research research includes themes of Apoptosis, B cell, Cytotoxicity, Kinase and In vivo. John C. Byrd interconnects Clinical trial, Chemotherapy, Phases of clinical research and Chemoimmunotherapy in the investigation of issues within Oncology.
His primary areas of investigation include Internal medicine, Chronic lymphocytic leukemia, Oncology, Cancer research and Ibrutinib. His work on Leukemia, Rituximab, Cancer and Venetoclax as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Chronic lymphocytic leukemia research incorporates themes from Relapsed refractory, B cell and Phases of clinical research.
His Oncology research is multidisciplinary, incorporating elements of Clinical trial, Refractory, Chemotherapy and NPM1. John C. Byrd combines subjects such as Cell culture, Bruton's tyrosine kinase, In vivo and Cytotoxicity with his study of Cancer research. His Ibrutinib study also includes
His primary scientific interests are in Internal medicine, Chronic lymphocytic leukemia, Ibrutinib, Leukemia and Oncology. As part of one scientific family, John C. Byrd deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gastroenterology, and often Progressive disease. His studies in Chronic lymphocytic leukemia integrate themes in fields like Cancer research, Neutropenia and Bruton's tyrosine kinase.
His study on Ibrutinib also encompasses disciplines like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh;Michael B. Eisen;R. Eric Davis;Izidore S. Lossos.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Pierre Fenaux;Ghulam J. Mufti;Eva Hellstrom-Lindberg;Valeria Santini.
Lancet Oncology (2009)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn.
The New England Journal of Medicine (2013)
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
John C. Byrd;Krzysztof Mrózek;Richard K. Dodge;Andrew J. Carroll.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos.
The New England Journal of Medicine (2014)
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon.
Journal of Experimental Medicine (2001)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet.
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia
Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen.
The New England Journal of Medicine (2004)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach;Richard R. Furman;Ta Ming Liu;Hatice Gulcin Ozer.
The New England Journal of Medicine (2014)
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
Ramiro Garzon;Shujun Liu;Muller Fabbri;Zhongfa Liu.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: